Literature DB >> 18688091

Assessing the toxicity of tau aggregation.

Carolyn A Rankin1, T Chris Gamblin.   

Abstract

Abnormally phosphorylated and aggregated tau protein is the primary component of pathological structures that are closely associated with neurodegeneration in Alzheimer's disease, Pick disease, corticobasal degeneration, progressive supranuclear palsy and many other neurodegenerative tauopathies, leading to the hypothesis that these structures are toxic mediators of disease progression. Results from animal models designed to test this hypothesis have yielded evidence that can suggest either a pathogenic, beneficial, or incidental role for tau aggregation. This review summarizes the differences in construction of recent model systems and assay methods that examine tau pathology and toxicity. We have found that the expression levels of tau and the modifications of tau used to enhance its aggregation have a large impact on the results. It is clear from the data that tau aggregation is toxic, but it is less clear which form of tau aggregate is the toxic species.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18688091     DOI: 10.3233/jad-2008-14408

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  13 in total

1.  Do amyloid-lowering strategies work clinically?

Authors:  Rob J van Marum
Journal:  Ther Adv Neurol Disord       Date:  2009-01       Impact factor: 6.570

2.  Formation of Hirano bodies after inducible expression of a modified form of an actin-cross-linking protein.

Authors:  Juan F Reyes; Karen Stone; Jeanie Ramos; Andrew Maselli
Journal:  Eukaryot Cell       Date:  2009-04-10

3.  MSUT2 is a determinant of susceptibility to tau neurotoxicity.

Authors:  Chris R Guthrie; Lynne Greenup; James B Leverenz; Brian C Kraemer
Journal:  Hum Mol Genet       Date:  2011-02-25       Impact factor: 6.150

Review 4.  Poly(A) RNA-binding proteins and polyadenosine RNA: new members and novel functions.

Authors:  Callie P Wigington; Kathryn R Williams; Michael P Meers; Gary J Bassell; Anita H Corbett
Journal:  Wiley Interdiscip Rev RNA       Date:  2014-04-30       Impact factor: 9.957

Review 5.  The senescence hypothesis of disease progression in Alzheimer disease: an integrated matrix of disease pathways for FAD and SAD.

Authors:  Sally Hunter; Thomas Arendt; Carol Brayne
Journal:  Mol Neurobiol       Date:  2013-04-03       Impact factor: 5.590

6.  The earliest tau dysfunction in Alzheimer's disease? Tau phosphorylated at s422 as a toxic seed.

Authors:  Kellen Voss; John Koren; Chad A Dickey
Journal:  Am J Pathol       Date:  2011-09-28       Impact factor: 4.307

7.  Secondary nucleating sequences affect kinetics and thermodynamics of tau aggregation.

Authors:  Christopher L Moore; Michael H Huang; Shauna A Robbennolt; Kellen R Voss; Benjamin Combs; T Chris Gamblin; Warren J Goux
Journal:  Biochemistry       Date:  2011-11-29       Impact factor: 3.162

8.  FTDP-17 tau mutations induce distinct effects on aggregation and microtubule interactions.

Authors:  Benjamin Combs; T Chris Gamblin
Journal:  Biochemistry       Date:  2012-10-18       Impact factor: 3.162

9.  Brains with medial temporal lobe neurofibrillary tangles but no neuritic amyloid plaques are a diagnostic dilemma but may have pathogenetic aspects distinct from Alzheimer disease.

Authors:  Peter T Nelson; Erin L Abner; Frederick A Schmitt; Richard J Kryscio; Gregory A Jicha; Karen Santacruz; Charles D Smith; Ela Patel; William R Markesbery
Journal:  J Neuropathol Exp Neurol       Date:  2009-07       Impact factor: 3.685

10.  Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization.

Authors:  Qian Sun; T Chris Gamblin
Journal:  Biochemistry       Date:  2009-06-30       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.